Figure 3. Targeting dividing stem cells from P0–P7 leads to depletion of the DG stem cell pool and decreased neurogenesis in adulthood.

(A) Experimental timeline of P0–P7 VGCV treatment and tamoxifen (TMX) administration in GFAP-Tk/Nestin-CreER^T2 mice. (B) Representative images of EYFP, DCX, NeuN, and GFAP staining in P0–P7 VGCV treated Tk− and Tk+ animals. (C) P0–P7 VGCV led to fewer EYFP+ cells in Tk+ versus Tk− males. (D) P0–P7 VGCV reduced the number of DCX+ immature and NeuN+DCX− mature neurons within the Nestin lineage of Tk+ compared to Tk− males. (E) P0–P7 VGCV led to fewer EYFP+ cells in Tk+ versus Tk− females. (F) P0–P7 VGCV reduced the number of DCX+ immature and NeuN+DCX− mature neurons within the Nestin lineage of Tk+ compared to Tk− females. (G) P0–P7 VGCV decreased the number of RGLs and increased the number of atypical astrocytes, but did not affect the number of stellate astrocytes within the Nestin lineage of Tk+ males and (H) females compared to Tk− animals. (I) P0–P7 VGCV led to fewer Nestin-S100β- and Nestin+S100β- RGLs, but did not change the number of S100β+ (including both Nestin-S100β+ and Nestin+S100β+) RGLs within the Nestin lineage of Tk+ versus Tk− males. (J) P0–P7 VGCV led to fewer Nestin-S100β-, Nestin+S100β-, and S100β+ RGLs within the Nestin lineage of Tk+ versus Tk− females. Scale bar represents 150 μM. GFAP inset is at 2× magnification. Data are expressed as mean ± SEM. *p≤0.05, **p<0.01, ***p<0.001